AU2017298873B2 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
AU2017298873B2
AU2017298873B2 AU2017298873A AU2017298873A AU2017298873B2 AU 2017298873 B2 AU2017298873 B2 AU 2017298873B2 AU 2017298873 A AU2017298873 A AU 2017298873A AU 2017298873 A AU2017298873 A AU 2017298873A AU 2017298873 B2 AU2017298873 B2 AU 2017298873B2
Authority
AU
Australia
Prior art keywords
emulsion
pharmaceutically
hpmc
oil
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017298873A
Other languages
English (en)
Other versions
AU2017298873A1 (en
Inventor
Romain BORDES
Simon Peter Michael Hjelm Jonasson
Christian Von Corswant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2017298873A1 publication Critical patent/AU2017298873A1/en
Application granted granted Critical
Publication of AU2017298873B2 publication Critical patent/AU2017298873B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2017298873A 2016-07-08 2017-07-06 Pharmaceutical compositions Ceased AU2017298873B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1611920.8 2016-07-08
GBGB1611920.8A GB201611920D0 (en) 2016-07-08 2016-07-08 Pharmaceutical compositions
PCT/EP2017/066983 WO2018015175A1 (en) 2016-07-08 2017-07-06 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU2017298873A1 AU2017298873A1 (en) 2019-02-14
AU2017298873B2 true AU2017298873B2 (en) 2020-04-30

Family

ID=56890842

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017298873A Ceased AU2017298873B2 (en) 2016-07-08 2017-07-06 Pharmaceutical compositions

Country Status (20)

Country Link
US (1) US20200254046A1 (enExample)
EP (1) EP3481377A1 (enExample)
JP (1) JP2019520393A (enExample)
KR (1) KR20190026816A (enExample)
CN (1) CN109414409A (enExample)
AU (1) AU2017298873B2 (enExample)
BR (1) BR112019000240A2 (enExample)
CA (1) CA3029331A1 (enExample)
CL (1) CL2019000042A1 (enExample)
CO (1) CO2019000083A2 (enExample)
CR (1) CR20190007A (enExample)
DO (1) DOP2019000002A (enExample)
EA (1) EA201990162A1 (enExample)
GB (1) GB201611920D0 (enExample)
IL (1) IL263999A (enExample)
MX (1) MX2019000255A (enExample)
PE (1) PE20190321A1 (enExample)
PH (1) PH12019500024A1 (enExample)
SG (1) SG11201811223YA (enExample)
WO (1) WO2018015175A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022071463A1 (ja) * 2020-10-02 2022-04-07 住友精化株式会社 粘性組成物
JPWO2022071461A1 (enExample) * 2020-10-02 2022-04-07

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465988A (en) * 2008-12-03 2010-06-09 Omegatri As Powder or tablet containing unsaturated fatty acid and water insoluble carbohydrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378444B2 (en) * 2002-06-17 2008-05-27 Brigham And Women's Hospital, Inc. Analogues of lipid mediators derived from omega-3 PUFAs and methods of use
WO2008145183A1 (en) * 2007-05-30 2008-12-04 Nestec S.A. Oil-in-water emulsion and its use for the delayed release of active elements
CN102421422A (zh) * 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
CN102512664B (zh) * 2010-12-31 2015-04-01 舒泰神（北京）生物制药股份有限公司 一种神经生长因子组合物
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465988A (en) * 2008-12-03 2010-06-09 Omegatri As Powder or tablet containing unsaturated fatty acid and water insoluble carbohydrate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
RAFFAELE MEZZENGA ET AL, "Spray-Dried Oil Powder with Ultrahigh Oil Content", LANGMUIR, US, (2010-11-16), vol. 26, no. 22, doi:10.1021/la103447n, ISSN 0743-7463, pages 16658 - 16661. *
SANGUANSRI L ET AL, JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY (JAOCS), SPRINGER, DE, vol. 93, no. 5, doi:10.1007/S11746-016-2807-8, ISSN 0003-021X, (2016-03-10), pages 701 - 710, (2016-03-10). *
ZHEN HU ET AL, "Dried and Redispersible Cellulose Nanocrystal Pickering Emulsions", ACS MACRO LETTERS, (2016-02-16), vol. 5, no. 2, doi:10.1021/acsmacrolett.5b00919, ISSN 2161-1653, pages 185 - 189. *
ZHEN HU ET AL, ACS SUSTAINABLE CHEMISTRY & ENGINEERING, US, (2015-05-04), vol. 3, no. 5, doi:10.1021/acssuschemeng.5b00194, ISSN 2168-0485, pages 1023 - 1031. *

Also Published As

Publication number Publication date
IL263999A (en) 2019-01-31
CN109414409A (zh) 2019-03-01
JP2019520393A (ja) 2019-07-18
CA3029331A1 (en) 2018-01-25
KR20190026816A (ko) 2019-03-13
GB201611920D0 (en) 2016-08-24
EP3481377A1 (en) 2019-05-15
CO2019000083A2 (es) 2019-01-18
PH12019500024A1 (en) 2019-11-04
EA201990162A1 (ru) 2019-06-28
WO2018015175A1 (en) 2018-01-25
PE20190321A1 (es) 2019-03-04
CR20190007A (es) 2019-03-05
SG11201811223YA (en) 2019-01-30
US20200254046A1 (en) 2020-08-13
WO2018015175A9 (en) 2018-03-29
MX2019000255A (es) 2019-05-27
AU2017298873A1 (en) 2019-02-14
BR112019000240A2 (pt) 2019-04-16
CL2019000042A1 (es) 2019-04-12
DOP2019000002A (es) 2019-03-31

Similar Documents

Publication Publication Date Title
Pinto et al. Design of multifunctional nanostructured lipid carriers enriched with α-tocopherol using vegetable oils
CA2802767C (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
US20240261254A1 (en) Dihydromyricetin nanoemulsion formulations and methods for forming them
Youan et al. Protein release profiles and morphology of biodegradable microcapsules containing an oily core
JP7671693B2 (ja) 非クルクミノイドの水溶性粒子とクルクミノイドの水溶性粒子から構成される製剤
Raffin et al. Natural lipid nanoparticles containing nimesulide: synthesis, characterization and in vivo antiedematogenic and antinociceptive activities
JP4028642B2 (ja) 乳化粉末の製造方法
Deepak et al. Nanostructured lipid carriers: A platform to lipophilic drug for oral bioavailability enhancement
US20200254046A1 (en) Pharmaceutical compositions
Nnamani et al. Physicochemical characterization of artemether-entrapped solid lipid microparticles prepared from templated-compritol and Capra hircus (goat fat) homolipid
WO2008073731A2 (en) Microemulsion dosage forms of valsartan and methods of making the same
Xia et al. Formulation, characterization and hypersensitivity evaluation of an intravenous emulsion loaded with a paclitaxel–cholesterol complex
JP2012017326A (ja) 難溶物を含有するカプセルとその製造方法
RU2765946C1 (ru) Система доставки сверхнасыщаемых самонаноэмульгирующихся лекарственных средств (SNEDDS) для слаборастворимых в воде фармацевтических композиций и способ ее приготовления
JP4282730B2 (ja) 乳化粉末の製造方法
EP0972513B1 (en) Process for preparing emulsified powder
Candiani et al. Solid lipid discs from water-in-oil emulsion as controlled release delivery systems of highly soluble drugs
Nguyen Extrusion-spheronization of pharmaceutical products: system for the delivery of active ingredients which are poorly soluble by oral route
Sabillah et al. Self-Nanoemulsifying Drug Delivery System (SNEDDS): challenges and opportunities in enhancing drug solubility
Nguyen et al. Nutraceutical compounds encapsulated by extrusion–spheronization
JP2010275249A (ja) 化粧料
WO2022096706A1 (en) Stable nanoemulsions
KR101475110B1 (ko) 허수테논 화합물의 안정화를 위한 제형
EP2884964A2 (en) Pharmaceutical composition of propofol
Ezegbe et al. PHARMACEUTICAL SCIENCES

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired